It has been known for decades that cancer cells have an altered metabolism, seen in several biochemical pathways and in particular in the way they get energy for their survival.

If healthy cells use the mitochondrial respiratory chain, tumours use aerobic glycolysis, a process that allows them to take energy quickly depending on glucose levels.

This phenomenon - known as the Warburg effect - is caused by several changes that take place during cell transformation.

Now, a new article describes an epigenetic injury found in human tumours which created this altered path to take energy from the cancer. The study, published in Journal of Clinical Investigation Insight, is new research carried out by a group led by Manel Esteller, Professor of Genetics of the Faculty of Medicine and Health Sciences of the University of Barcelona (UB), ICREA researcher, coordinator of the Cancer Epigenetics and Biology Program at IDIBELL, and director of the Josep Carreras Institute.

According to Professor Esteller, who led the new scientific study, "we found squamous tumours - in the head, neck, oesophagus and cervix - show activity loss of the SVIP gen, which prevents deterioration of proteins that are important for cell balance.

The fault in the SVIP gene function causes the destruction of the metabolic mechanisms that allow glucose's physiologic use to get energy in a controlled way, and which is finally replaced by a kind of molecular 'fast food' that gets cheap energy for the tumour cell".

"We have also seen patients with this metabolic change that show a shorter survival over the course of their disease", continues Esteller. "However, cancer cells' addiction to glucose could be their weakness. Therefore, pre-clinical studies show that patients with the epigenetic loss of the SVIP gene are sensitive to drugs against glucose receptor, which block the entrance of this molecule and cause a kind of 'abstinence syndrome' of the tumour that holds their growth back".

Source: University of Barcelona

Article: Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming